The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer

Foulkes, Stephen, Daly, Robin M. and Fraser, Steve F. 2017, The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer, Endocrine-related cancer, vol. 24, no. 3, pp. R35-R48, doi: 10.1530/ERC-16-0505.

Attached Files
Name Description MIMEType Size Downloads

Title The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer
Author(s) Foulkes, Stephen
Daly, Robin M.ORCID iD for Daly, Robin M.
Fraser, Steve F.ORCID iD for Fraser, Steve F.
Journal name Endocrine-related cancer
Volume number 24
Issue number 3
Start page R35
End page R48
Total pages 14
Publisher BioScientifica
Place of publication Bristol, Eng.
Publication date 2017-03
ISSN 1479-6821
Keyword(s) androgen deprivation therapy
cardiometabolic risk
dual-energy X-ray absorptiometry
fat distribution
prostate cancer
visceral adipose tissue
Summary Androgen deprivation therapy (ADT) is now considered a mainstay in the treatment of metastatic and locally advanced prostate cancer (PCa). Despite well-established benefits of ADT in relation to overall survival, this treatment has been associated with a number of adverse effects, particularly with regard to key cardiometabolic risk factors including the development of insulin resistance, dyslipidemia and increases in total and regional fat mass. In non-ADT populations, increased levels of visceral adipose tissue (VAT) are thought to be a key mediator of the increased cardiometabolic risk associated with weight gain, but this has received limited attention in men treated with ADT. VAT is best assessed using tools such as computed tomography or magnetic resonance imaging; however, these tools are not readily accessible for the majority of researchers or clinicians. Recent advances allow for a method of estimating VAT using a whole-body dual-energy X-ray absorptiometry (DXA) scan that shows promise as a practical tool for researchers to evaluate changes in body fat distribution during ADT. The aim of this narrative review is to (1) review the available evidence with regard to the relationship between ADT and cardiometabolic risk; (2) discuss the role of body fat distribution on cardiometabolic risk in non-ADT populations, with a particular emphasis on the importance of visceral adiposity; (3) examine the potential influence of ADT on body fat distribution and visceral adiposity and (4) provide an overview of current tools used to measure changes in body fat distribution in men treated with ADT, highlighting the potential utility of a recently developed DXA-derived measure of VAT.
Language eng
DOI 10.1530/ERC-16-0505
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
11 Medical And Health Sciences
06 Biological Sciences
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2017, Society for Endochrinology
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
Institute for Physical Activity and Nutrition
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in TR Web of Science
Scopus Citation Count Cited 7 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 408 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Tue, 04 Apr 2017, 15:18:27 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact